Santhera Pharmaceuticals Holding AG (SANN) - Net Assets
Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) has net assets worth CHF-2.56 Million CHF (≈ $-3.24 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF130.77 Million ≈ $165.33 Million USD) and total liabilities (CHF133.33 Million ≈ $168.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Santhera Pharmaceuticals Holding AG asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF-2.56 Million |
| % of Total Assets | -1.96% |
| Annual Growth Rate | -9.03% |
| 5-Year Change | N/A |
| 10-Year Change | -73.93% |
| Growth Volatility | 834.67 |
Santhera Pharmaceuticals Holding AG - Net Assets Trend (2006–2024)
This chart illustrates how Santhera Pharmaceuticals Holding AG's net assets have evolved over time, based on quarterly financial data. Also explore Santhera Pharmaceuticals Holding AG asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Santhera Pharmaceuticals Holding AG (2006–2024)
The table below shows the annual net assets of Santhera Pharmaceuticals Holding AG from 2006 to 2024. For live valuation and market cap data, see market value of Santhera Pharmaceuticals Holding AG.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CHF27.70 Million ≈ $35.02 Million |
-53.79% |
| 2023-12-31 | CHF59.94 Million ≈ $75.78 Million |
+237.21% |
| 2022-12-31 | CHF-43.69 Million ≈ $-55.23 Million |
-3389.61% |
| 2021-12-31 | CHF1.33 Million ≈ $1.68 Million |
+120.90% |
| 2020-12-31 | CHF-6.35 Million ≈ $-8.03 Million |
-129.91% |
| 2019-12-31 | CHF21.25 Million ≈ $26.86 Million |
-23.65% |
| 2018-12-31 | CHF27.83 Million ≈ $35.18 Million |
-13.72% |
| 2017-12-31 | CHF32.26 Million ≈ $40.78 Million |
-56.62% |
| 2016-12-31 | CHF74.35 Million ≈ $94.00 Million |
-30.02% |
| 2015-12-31 | CHF106.25 Million ≈ $134.32 Million |
+516.35% |
| 2014-12-31 | CHF17.24 Million ≈ $21.79 Million |
+142.58% |
| 2013-12-31 | CHF7.11 Million ≈ $8.98 Million |
-39.42% |
| 2012-12-31 | CHF11.73 Million ≈ $14.83 Million |
-72.71% |
| 2011-12-31 | CHF42.98 Million ≈ $54.34 Million |
-38.27% |
| 2010-12-31 | CHF69.63 Million ≈ $88.03 Million |
-16.63% |
| 2009-12-31 | CHF83.51 Million ≈ $105.58 Million |
-20.06% |
| 2008-12-31 | CHF104.47 Million ≈ $132.08 Million |
-22.91% |
| 2007-12-31 | CHF135.51 Million ≈ $171.33 Million |
-10.87% |
| 2006-12-31 | CHF152.05 Million ≈ $192.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Santhera Pharmaceuticals Holding AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52413200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF1.34 Million | 4.85% |
| Other Comprehensive Income | CHF-3.30 Million | -11.90% |
| Other Components | CHF644.35 Million | 2326.32% |
| Total Equity | CHF27.70 Million | 100.00% |
Santhera Pharmaceuticals Holding AG Competitors by Market Cap
The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hannong Chem
KO:011500
|
$244.60 Million |
|
Ample Electronic Technology Co Ltd
TWO:4760
|
$244.63 Million |
|
Pennar Industries Limited
NSE:PENIND
|
$244.65 Million |
|
Falcon Oil & Gas Ltd.
V:FO
|
$244.71 Million |
|
Fifth Era Acquisition Corp I Class A Ordinary Shares
NASDAQ:FERA
|
$244.50 Million |
|
Martifer SGPS S.A
LS:MAR
|
$244.46 Million |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class B
IS:KRDMB
|
$244.44 Million |
|
Genfit S.A.
NASDAQ:GNFT
|
$244.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Santhera Pharmaceuticals Holding AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 59,943,000 to 27,698,000, a change of -32,245,000 (-53.8%).
- Net loss of 41,974,000 reduced equity.
- Share repurchases of 1,059,000 reduced equity.
- New share issuances of 1,059,000 increased equity.
- Other comprehensive income decreased equity by 4,312,000.
- Other factors increased equity by 14,041,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-41.97 Million | -151.54% |
| Share Repurchases | CHF1.06 Million | -3.82% |
| Share Issuances | CHF1.06 Million | +3.82% |
| Other Comprehensive Income | CHF-4.31 Million | -15.57% |
| Other Changes | CHF14.04 Million | +50.69% |
| Total Change | CHF- | -53.79% |
Book Value vs Market Value Analysis
This analysis compares Santhera Pharmaceuticals Holding AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.02x to 6.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CHF777.00 | CHF17.00 | x |
| 2007-12-31 | CHF437.06 | CHF17.00 | x |
| 2008-12-31 | CHF330.11 | CHF17.00 | x |
| 2009-12-31 | CHF235.61 | CHF17.00 | x |
| 2010-12-31 | CHF190.27 | CHF17.00 | x |
| 2011-12-31 | CHF117.28 | CHF17.00 | x |
| 2012-12-31 | CHF31.90 | CHF17.00 | x |
| 2013-12-31 | CHF19.16 | CHF17.00 | x |
| 2014-12-31 | CHF36.65 | CHF17.00 | x |
| 2015-12-31 | CHF193.76 | CHF17.00 | x |
| 2016-12-31 | CHF118.52 | CHF17.00 | x |
| 2017-12-31 | CHF51.45 | CHF17.00 | x |
| 2018-12-31 | CHF40.38 | CHF17.00 | x |
| 2019-12-31 | CHF19.33 | CHF17.00 | x |
| 2020-12-31 | CHF-4.77 | CHF17.00 | x |
| 2021-12-31 | CHF0.39 | CHF17.00 | x |
| 2022-12-31 | CHF-7.17 | CHF17.00 | x |
| 2023-12-31 | CHF5.49 | CHF17.00 | x |
| 2024-12-31 | CHF2.43 | CHF17.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Santhera Pharmaceuticals Holding AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -107.30%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 5.51x
- Recent ROE (-151.54%) is above the historical average (-276.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -18.58% | -3618.18% | 0.00x | 1.07x | CHF-43.46 Million |
| 2007 | -20.57% | -302.09% | 0.06x | 1.06x | CHF-41.42 Million |
| 2008 | -42.74% | -93033.33% | 0.00x | 1.08x | CHF-55.10 Million |
| 2009 | 31.04% | 1577.78% | 0.02x | 1.13x | CHF17.57 Million |
| 2010 | -16.17% | -54.62% | 0.26x | 1.13x | CHF-18.22 Million |
| 2011 | -64.76% | -852.62% | 0.06x | 1.21x | CHF-32.14 Million |
| 2012 | -268.10% | -888.86% | 0.19x | 1.56x | CHF-32.62 Million |
| 2013 | -80.99% | -436.32% | 0.14x | 1.37x | CHF-6.47 Million |
| 2014 | -43.71% | -290.78% | 0.11x | 1.33x | CHF-9.26 Million |
| 2015 | 5.60% | 137.68% | 0.04x | 1.10x | CHF-4.68 Million |
| 2016 | -47.63% | -186.07% | 0.21x | 1.22x | CHF-42.85 Million |
| 2017 | -159.76% | -224.61% | 0.21x | 3.40x | CHF-54.76 Million |
| 2018 | -194.71% | -171.17% | 0.29x | 3.96x | CHF-56.97 Million |
| 2019 | -89.30% | -25.17% | 0.66x | 5.41x | CHF-21.10 Million |
| 2020 | 0.00% | -450.82% | 0.17x | 0.00x | CHF-67.02 Million |
| 2021 | -4181.17% | 0.00% | -0.02x | 68.61x | CHF-55.66 Million |
| 2022 | 0.00% | -951.10% | 0.12x | 0.00x | CHF-66.71 Million |
| 2023 | 91.39% | 52.97% | 0.94x | 1.83x | CHF48.79 Million |
| 2024 | -151.54% | -107.30% | 0.26x | 5.51x | CHF-44.74 Million |
Industry Comparison
This section compares Santhera Pharmaceuticals Holding AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $144,219,224
- Average return on equity (ROE) among peers: -34.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Santhera Pharmaceuticals Holding AG (SANN) | CHF-2.56 Million | -18.58% | N/A | $244.59 Million |
| Addex Therapeutics Ltd (ADXN) | $33.84 Million | -92.04% | 0.29x | $7.10 Million |
| BB Biotech AG (BION) | $1.91 Billion | 10.59% | 0.00x | $2.25 Billion |
| Basilea Pharmaceutica AG (BSLN) | $125.38 Million | -47.04% | 0.20x | $699.48 Million |
| Evolva Holding SA (EVE) | $21.86 Million | -39.62% | 1.03x | $7.08 Million |
| Idorsia Ltd (IDIA) | $-1.21 Billion | 0.00% | 0.00x | $759.27 Million |
| Molecular Partners AG (MOLN) | $135.79 Million | -13.71% | 0.36x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $29.28 Million | -80.19% | 0.42x | $360.88 Million |
| Relief Therapeutics Holding AG (RLF) | $14.30 Million | -52.18% | 0.39x | $36.33 Million |
| Xlife Sciences AG (XLS) | $235.23 Million | 6.08% | 1.08x | $122.27 Million |
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more